Cambridge Equities LP 13D and 13G filings for ImmunityBio, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-03 9:59 pm Purchase |
2023-12-29 | 13D | ImmunityBio, Inc. IBRX |
Cambridge Equities LP | 696,162,179 83.500% |
45,949,213 (+7.07%) |
Filing |
| 2023-09-21 4:25 pm Purchase |
2023-09-11 | 13D | ImmunityBio, Inc. IBRX |
Cambridge Equities LP | 650,212,966 82.800% |
265,465,303 (+69.00%) |
Filing |
| 2023-05-22 7:15 pm Purchase |
2023-05-12 | 13D | ImmunityBio, Inc. IBRX |
Cambridge Equities LP | 384,747,663 77.300% |
14,991,427 (+4.05%) |
Filing |
| 2022-12-06 8:28 pm Purchase |
2022-08-31 | 13D | ImmunityBio, Inc. IBRX |
Cambridge Equities LP | 369,756,236 80.900% |
55,598,591 (+17.70%) |
Filing |
| 2021-03-12 2:59 pm Purchase |
2021-03-09 | 13D | ImmunityBio, Inc. IBRX |
Cambridge Equities LP | 314,157,645 81.900% |
314,157,645 (New Position) |
Filing |